With the monumental returns awarded to investors of Dendreon (DNDN) over the past few years on the road to the historical Provenge approval, many are still seeking that "next Dendreon" play. Often times, Oncothyreon (ONTY), with a Phase III cancer immunotherapeutic product candidate of its own, enters the discussions.
Oncothyreon has been receiving more than its fair share of attention these days, following the recent run that saw ONTY set some new 52-week highs and receive a couple of positive price projections from analysts along the way, and a recent stock offering wasn't enough to stall the price rise.
The stock offering, which added $40 million the Oncothyreon war chest, will fund the further development of its pipeline, which includes Stimuvax, an immunotherapeutic treatment for non-small cell lung cancer that is partnered with Germany'sMerck KGaA.
Results from the ongoing Stimuvax trials, which were halted for a brief time early last
Complete Story »